Genetically directed therapies are rapidly redefining the course of modern medicine including addiction treatment. Genetic researcher Dr. Kenneth Blum – co-discoverer of the first known addiction gene – and his co-authors lay out a comprehensive view of the future of addiction treatment through the identification of risk or vulnerability for both drug and alcohol severity combined with genetically directed therapies.
AUSTIN, Texas (PRWEB) March 05, 2018
‘The un-aimed arrow never misses’ is a phrase long associated with motivation and goal-setting; the implication being that if you do not aim for a specific goal than wherever the arrow lands is its destined target. The same logic can be applied to modern addiction treatment. We’ve lived through a long era of well-intended un-aim arrows landing on a wide swath of destructive addictive behaviors while missing the true and most consequential target of addiction, genetic predispositions; and that is about to radically change.
Genetically directed therapies are rapidly redefining the course of modern medicine including addiction treatment. Genetic researchers such as Dr. Kenneth Blum – co-discoverer of the first known addiction gene – have revealed to the world the inter workings of what makes us who we are. In Blum’s case, a literal blue print, if you will, of neuro-chemicals and their effects on behavior. But what has distinguished Dr. Blum from other researchers over the last thirty-years has been his relentless pursuit of the treatment for genetic predisposition to addiction.
In his forthcoming article being published by renowned addiction and recovery monthly periodical, Sober World Magazine, Dr. Blum, PhD, and co-authors David Siwicki, MD, and Jennifer Neary, PhD and Mary Hauser lay out a comprehensive view of the future of addiction treatment through the identification of risk or vulnerability for both drug and alcohol severity combined with genetically directed therapies. They believe that early detection of risk and treatment of the genetic drivers of addiction will play a critical role in curbing the opioid epidemic.
For over forty-years Dr. Blum has conducted extensive research worldwide in an effort to completely define the contributing aspects of genetic predisposition to addiction. One result of his comprehensive testing is a gene panel of ten reward gene risk variants. The Genetic Addiction Risk Score (GARS), a non-invasive genetic matrix panel, now makes it possible for an individual to know what their genetic risk or vulnerability to alcohol and/or drug addiction. This information can prove invaluable in clinical interactions and decision-making, especially in choosing pain medications.
Moreover, the information gained through testing led Dr. Blum and his team to develop all natural neuro-nutrients that help restore brain function by targeting specific neuro-chemicals whose function is genetically compromised – and as such – contribute to genetic predisposition to addiction. These neuro-nutrients – which have been used to manage addiction recovery in leading treatment centers across the country for years – have been scientifically proven to reduce or eliminate excessive desires for unhealthy behaviors and pleasure-inducing substances.
Dr. Blum and his co-authors go into great detail about GARS and the genetically directed all natural neuro-nutrients in their article titled ‘Promoting Precision Addiction Management (PAM) ™ To Combat the Global Opioid Crisis’ set to be published in the prestigious Sober World Magazine March 2018 edition and online at http://www.thesoberworld.com.
To learn more about Genetic Addiction Risk Score (GARS) and/or the genetically directed all-natural neuro-nutrients please visit http://www.geneushealth.com or call 844-800-2334.
For the original version on PRWeb visit: http://www.prweb.com/releases/2018/03/prweb15269228.htm